All Type of News
FTA threatens Korea to leap up for new drug R&D
The KPMA sensitively worries that the guarantee of patent issues under the KORUS FTA agreement might cause local drug industries to lose a leap-up chance for lifting Korea to the nations of new drug development.
...
Generic giants to get easier access to Korean pharmaceutical market
The Korea-U.S. free trade agreement is expected to make it easier for foreign generic giants, Ranbaxy Laboratories Limited, to open businesses in the domestic pharmaceutical market.
Ranbaxy is India's largest pharm...
Drug makers to adopt holding company system
Choong-wae Pharm has stepped up its restructuring efforts to adopt a holding company system for securing its managerial right and maintaining a corporate spirit, as the domestic pharmaceutical sector is expected to fa...
FTA to give adverse impact to wholesaler's profitability.
The drug industry as well as wholesalers have faced with a big business damage especially over generic drugs under the FTA far beyond their earlier expectation when it's reality was surfaced.
The local drug wholesa...
Big wholesalers' influence up
Large drug wholesalers with sales grater than 200 billion won saw their combined market share continue to increase steadily in 2006, exerting influence on the overall wholesaling industry.
According to the tallie...
FTA will encourage more competitiveness of Korean drug makers, health ministry saysThe Ministry of Health and Welfare said on April 2 that the free trade agreement (FTA) reached between Korea and the U.S. will help enhancing the competitive power of local drug...
|
Concerns growing over public health
The end of the free trade agreement (FTA) will be a big blow to Korean pharmaceutical firms that rely much of the revenue on the sales of generic drugs, and also threaten the government's ability to control the prices...
FTA to batter generic drug business and raise patent disputes.
It is expected that the KORUS FTA settlement may raise a lot of patent disputes between the original drug companies and generic drug manufacturers, and if any patent lawsuit be raised, its copy drug registration may b...
FTA negotiation battles on pharmaceutical issues ended in defeat.
9 round talks on the KORUS FTA negotiations since June last year were finally settled down.
The pharmaceutical issues were one of the hottest subjects to an extent that during the 2nd talks in Seoul, the U. S. nego...
KFDA announces voluntary withdrawal of Zelmac
The Korea Food and Drug Administration (KFDA) announced on April 2 that Novartis Korea has halted sales of Zelmac (tegaserod), its agent for irritable bowel syndrome and constipation, following suggestions of a small ...
